| Working from publicly available company information
(including SEC filings, Web site material, company press releases, etc.),
and with input from company executives, the DERG staff develops
a detailed, highly-structured, yet easily understandable
Investor's Corporate Profile®
of your company.
The ICP® is not designed to provide traditional Wall Street
analysis of a firm. Instead, it provides a summary of all
relevant factual information, especially its market
opportunities, products (commercial and in development),
technologies, competition, financial performance, and strategic
alliances, partnerships, collaborations, etc. It does not
include buy/sell ratings or provide target stock prices, does
not forecast the market, and does not recommend buys, sells, or
holds.
Each Profile is written with the average (but serious)
investor in mind. It explains your company's mission, growth
strategy, product line and product pipeline, unique and
promising technologies, and much more. It also provides a SWOT
analysis (Strengths, Weaknesses, Opportunities, Threats),
written by the editorial staff of Stem Cell Business News.
The Profile is based on facts, not on speculation or arcane
financial forecasting, and therefore provides an ideal overview
of your company that can be provided in print or PDF format free of charge to potential
investors, either in PDF format or in a print version.
For Profile pricing information,
.
To view a sample of an Investor's Corporate Profile®,
click on the link below. |
|
